No survival benefit with early treatment of relapse on the basis of a raised CA125 concentration

Cancer antigen 125 (CA125) The findings of the first randomised trial to investigate timing of treatment for relapsed ovarian cancer was published in the October 2, 2010 issue of the Lancet. The level of the CA125 protein produced by ovarian cancer cells in the blood often increases several months before signs or symptoms of relapse […]

read more
Page 6 of 8« First...«45678»